

Primary Pulmonary Synovial Sarcoma: A Rare Lung Tumor

Sabarigirivasan Harish VK*, Venkateswara Babu R, Banushree Chandrasekhar, Srinivas Murthy, Loknath B, Hariharan

Department of Respiratory Medicine, Indira Gandhi Medical College and Research Institute, Puducherry, India

Abstract

Pulmonary synovial sarcoma represents a rare form of lung malignancy when juxtaposed with others. The diagnosis of primary pulmonary sarcoma is usually made after ruling out the common primary lung malignancies and metastatic sarcomas. Metastatic synovial sarcoma of the lung occurs more frequently than primary pulmonary synovial sarcoma. The usual presentation will be cough, chest pain, breathlessness and radiologically a mass in the lung. Histopathological examination and immunohistochemical staining of the biopsy sample are needed to confirm the diagnosis; if possible genetic study should also be done. Since the tumor is very rare, we describe the case of a 66-year-old woman presenting with a large right lung mass and ipsilateral pleural effusion, diagnosed as pulmonary synovial sarcoma via ultrasound-guided lung biopsy.

Keywords: Pulmonary synovial sarcoma, TLE1, Surgical excision.

INTRODUCTION

Pulmonary synovial sarcoma is a rare lung tumor, making up about 0.5% of all primary lung cancers.¹ It is an aggressive tumor originating from mesenchymal tissues. It commonly affects the periarticular sites but very rarely involves the lung.² It is more common in males.² “The non-specific clinical and radiological features of this tumor make its diagnosis challenging. Therefore, histopathological examination along with immunohistochemistry is essential for definitive diagnosis. TLE1 is a specific and sensitive IHC marker for synovial sarcoma, which aids in differentiating it from its histologic mimics. To establish the diagnosis, other common primary lung tumors must be excluded. As of yet, only a limited number of cases have been documented in the literature.

Case Report

A 66-year-old female who is a daily wager, presented with breathlessness and chest pain for 3 months. Breathlessness was progressive, grade IV at the time of admission, and was associated with orthopnea. She had a myocardial infarction 10 years ago and started on antiplatelet drugs. No other significant past history was there. No history of any substance addiction was disclosed. Routine blood investigations were

normal. ECG was done, showed old ischemic changes (Q waves seen in II, III, and aVF), and Trop T was negative. A chest X-ray was done, which showed homogenous opacity in the right middle and lower zones with some lucency in the lower zone, and the costophrenic angle was obliterated (Figure 1A). The upper border of the lesion was lobulated, suggesting suspicion of a mass lesion and loculated effusion. The CECT chest showed a right-sided well-defined heterogeneous mass lesion occupying 2/3rd of the hemithorax and abutting the mediastinal structures (Figure 1B). There was also a collection in the right pleural space, which was aspirated under USG guidance and sent for analysis. The analysis of the pleural fluid revealed an exudative lymphocytic effusion, characterized by low ADA levels (22 U/L) and the absence of malignant cells. Whole-body CT was done to rule out metastasis in other sites. USG guided lung FNAC, and a biopsy was done. Lung FNAC was inconclusive, and the biopsy specimen revealed a biphasic tumor with predominantly monomorphic spindle cells arranged in fascicles and a palisading pattern (Figure 1C). The spindle cells were seen

Address for correspondence: Sabarigirivasan Harish VK

Department of Respiratory Medicine, Indira Gandhi Medical College and
Research Institute, Puducherry, India
E-mail: sabarigirivasan103@gmail.com

Access this article online

Quick Response Code



Website: uapmjournals.in

DOI: 10.70192/v3.i1.05

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Harish SVK, Babu VR, Chandrasekhar B, Murthy S, Loknath B, Hariharan. Primary Pulmonary Synovial Sarcoma: A Rare Lung Tumor. UAPM J. Respiratory Diseases Allied Sci. 2026;3(1):24-26.

Received: 02-12-2025, **Accepted:** 28-01-2026, **Published:** 12-02-2026




Figure 1: (A) - Chest X-ray shows Homogeneous opacity in the right middle and lower zones with focal lucency inferiorly and obliteration of the costophrenic angle. (B) - CECT chest shows a right-sided heterogeneous mass lesion occupying 2/3rd of the hemithorax and abutting the mediastinal structures with pleural effusion. (C) - HPE shows a biphasic tumor with predominantly monomorphic spindle cells arranged in fascicles and a palisading pattern on TLE1 staining




Figure 2: Immunohistochemical staining of lung mass biopsy showing negative staining for Desmin (A), positive for S100 (B), Cd99 (C) and Bcl2 (D)

with hyperchromatic nuclei and scanty cytoplasm (stubby nuclei). For further confirmation, immunohistochemical staining was done. TLE1, CD99, Bcl2 and S100 were positive (Figure 2A). Desmin (Figure 2B-D) and SMA were negative. There was no evidence of metastasis in any other sites. The final impression was primarily biphasic synovial sarcoma. Since the treatment of choice for this condition is surgery followed by chemotherapy, the patient was referred to cardio thoracic surgeon for surgical intervention.

DISCUSSION

Synovial sarcoma is a misnomer, as the tumor originates from mesenchymal cells rather than the synovium. However,

the tumor histologically resembles the synovial tissue, it was named synovial sarcoma. It is more common in males. Breathlessness, cough, and chest pain are the commonest symptoms.³ Usually presents as a central tumor and is rare to present as a peripheral lesion. On radiological examination, the mass lesion appears well-defined and heterogeneous, featuring necrotic areas and an accompanying pleural effusion. Lymphadenopathy is usually rare in this tumor, which is evident in our case.⁴

Synovial sarcoma comprises four histological variants: monophasic fibrous, monophasic epithelial, biphasic, and poorly differentiated.⁵ Biphasic sarcoma is the most common, as observed in our case.⁶ In the biphasic type, both epithelial and

sarcoma components will be present. Immunohistochemical markers like CD99, S100, Bcl2, vimentin, desmin, and TLE1 help to confirm the diagnosis.^{7,8} TLE1 serves as a highly sensitive and specific immunohistochemical (IHC) marker for the diagnosis of synovial sarcoma that aids in differentiating it from synovial sarcoma from other that histologic mimics of synovial sarcoma.⁹ The gold standard investigation of this tumor is the demonstration of chromosomal abnormality (translocation X:18), which is present in almost 90% of the patients. This translocation fuses the SYT gene on chromosome 18 with the SXX1 or SXX2 genes at Xp11. The resulting SYT–SSX1 or SYT–SSX2 fusion transcripts alter cellular transcription. Biphasic tumors generally express the SYT–SSX1 fusion, but monophasic tumors can express either type. In our case, the diagnosis was confirmed with histopathological examination and immunohistochemical staining. We could not do the genetic study due to non-availability of the test in our setup, which is a limitation in our report.¹⁰

The mainstay of treatment is surgery, chemotherapy, and radiotherapy.¹¹ Patients with locally invasive disease or metastasis, surgery is not recommended. This tumor is relatively chemo sensitive. A treatment regimen using Adriamycin, either alone or in combination with ifosfamide, is used particularly in cases with metastasis.¹² The 5-year survival rate of pulmonary synovial sarcoma is less compared to synovial sarcoma in other sites (30 vs 50%). Poor prognostic factors of this tumor are young age < 20 years, male gender, size of the tumor >5 cm, extensive necrosis, presence of high mitotic figures, and neurovascular involvement.¹³ Since our patient had a huge tumor occupying almost 2/3 of the hemithorax and associated with pleural effusion, we referred our case to the CTVS department for further management.

CONCLUSION

Rare tumors may present with non-specific clinical and radiological features, which need an extensive workup to make a final diagnosis. In our case, histopathology along with immunohistochemical staining played a very important role in the diagnosis, to the level where no need to go for gold standard investigation (genetic study).

REFERENCES

1. Keel SB, Bacha E, Mark EJ, Nielsen GP, Rosenberg AE. Primary pulmonary sarcoma: a clinicopathologic study of 26 cases. *Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc.* 1999 Dec 1;12(12):1124-31.
2. Mankin HJ, Hornicek FJ. Diagnosis, classification, and management of soft tissue sarcomas. *Cancer control.* 2005 Jan;12(1):5-21.
3. Essary LR, Vargas SO, Fletcher CD. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. *Cancer.* 2002 Jan 15;94(2):459-69.
4. Marak JR, Raj G, Khanna T, Singh P, Harsha G. Primary monophasic synovial sarcoma of the lung: Rare case report. *Radiology Case Reports.* 2023 Jun 1;18(6):2212-28.
5. Kottu R, Prayaga AK. Synovial sarcoma with relevant immunocytochemistry and special emphasis on the monophasic fibrous variant. *Journal of Cytology.* 2010 Apr 1;27(2):47-50.
6. Siegel HJ, Sessions W, Casillas Jr MA, Said-Al-Naief N, Lander PH, Lopez-Ben R. Synovial sarcoma: clinicopathologic features, treatment, and prognosis. *Orthopedics.* 2007 Dec 1;30(12):1020.
7. Dei Tos AP. Immunohistochemical demonstration of glycoprotein p30/32MIC2 in synovial sarcoma: a potential cause of diagnostic confusion. *Appl Immunohistochem.* 1995; 3: 168-73.
8. Braham E, Aloui S, Aouadi S, Drira I, Kilani T, El Mezni F. Synovial sarcoma of the chest wall: a case report and literature review. *Annals of translational medicine.* 2013 Apr;1(1):9.
9. Lino-Silva LS, Flores-Gutiérrez JP, Vilches-Cisneros N, Domínguez-Malagón HR. TLE1 is expressed in the majority of primary pleuropulmonary synovial sarcomas. *Virchows Archiv.* 2011 Dec; 459:615-21.
10. Nuwal P, Dixit R, Shah NS, Samaria A. Primary monophasic synovial sarcoma lung with brain metastasis diagnosed on transthoracic FNAC: Report of a case with literature review. *Lung India.* 2012 Oct 1;29(4):384-7.
11. Treglia G, Caldarella C, Taralli S. A Rare Case of Primary Pulmonary Synovial Sarcoma in a Pediatric Patient Evaluated by 18F-FDG PET/CT. *Clinical nuclear medicine.* 2014 Feb 1;39(2): e166-8.
12. Dole S, Barthwal MS. An unusual case of primary pulmonary synovial sarcoma. *The Egyptian Journal of Bronchology.* 2024 Nov 28;18(1):95.
13. Bunch K, Deering SH. Primary pulmonary synovial sarcoma in pregnancy. *Case Reports in Obstetrics and Gynecology.* 2012;2012(1):326031.